Latest Cytosorbents Cor (CTSO) Headlines
CytoSorbents Corporation Announces $10,200,000 Registered Direct Offering
PR Newswire - Fri Mar 07, 8:31AM CST
CytoSorbents Corporation (OTCBB: CTSO), a Nevada corporation, today announced that it has entered into subscription agreements with certain institutional investors to sell approximately $10,200,000 of its common stock and warrants to purchase common stock in a registered direct offering.
Vista Partners Publishes March 2014 Macroeconomic & Investment Newsletter
Marketwire - Fri Mar 07, 8:00AM CST
Vista Partners ("Vista") announced today that it published its FREE Macroeconomic & Investment Monthly Newsletter for the month of March. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary.
National Institutes of Health Grant Urges Latino Males to Receive Free Confidential HIV Testing
PR Newswire - Wed Jan 29, 7:30AM CST
Today marks the launch of "Conoces a Pepe? Have you met Pepe?," a social impact campaign focusing on educating and mobilizing Hispanic/Latino communities to live their best life with HIV testing and taking responsibility for their health.
Stryker Hits 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 9:20AM CST
Shares of Stryker Corporation were favorably affected by its announcement of acquiring Irvine, Calif.-based Patient Safety Technologies
CytoSorbents to Exhibit at the 43rd Society of Critical Care Medicine Congress and Present at the Biotech Showcase 2014
Marketwire - Tue Jan 07, 8:01AM CST
CytoSorbents Corporation (OTCBB: CTSO), a critical care immunotherapy company, announced that it will exhibit its CytoSorb(R) and HemoDefend(TM) technologies at the Society of Critical Care Medicine (SCCM) 43rd Critical Care Congress from January 10-12, 2014 at the Moscone Center South in San Francisco, California in Booth 918. More than 4,000 critical care clinicians from the U.S. and abroad are expected to attend.
CytoSorbents Reports on Successful DIVI 2013 Conference
Marketwire - Mon Dec 16, 7:31AM CST
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company commercializing its European Union approved CytoSorb(R) blood filter to treat life-threatening illnesses in the intensive care unit, reports on its recent activities at the DIVI 2013 Congress in Leipzig, Germany.
Biocon Partners With CytoSorbents to Market CytoSorb(R) -- A 'First-in-Class' Therapy for Sepsis Management
Marketwire - Fri Sep 13, 7:01AM CDT
Biocon Ltd, Asia's largest biotech company, and CytoSorbents Corporation (OTCQB: CTSO), based in the United States, announced today, World Sepsis Day, that they have entered into a strategic partnership with an initial distribution agreement for India and select emerging markets, under which Biocon will have the exclusive commercialization rights for CytoSorb(R), a novel therapy for the management of sepsis.
Stop Sepsis. Save Lives. CytoSorbents Sponsors Global Sepsis Alliance and Sepsis Heroes in Honor of World Sepsis Day
Marketwire - Thu Sep 12, 5:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a leading innovator in the use of blood purification to treat critical illnesses such as sepsis, is a proud sponsor of both the Global Sepsis Alliance and the Sepsis Heroes event hosted by the Sepsis Alliance tonight in New York City, in honor of the second annual World Sepsis Day tomorrow.
CytoSorbents Awarded $203K Phase I SBIR Contract from NHLBI/NIH for HemoDefend(TM)
Marketwire - Mon Sep 09, 11:45AM CDT
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company specializing in blood purification, announced today that the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded the Company a Phase I SBIR (Small Business Innovation Research) contract to further advance its HemoDefend(TM) blood purification technology for packed red blood cell (pRBC) transfusions. The project, entitled "Elimination of blood contaminants from pRBCs using HemoDefend hemocompatible porous polymer beads," is valued at $203,351 over 6 months, with funding to start immediately.
CytoSorbents to Present at the Rodman & Renshaw Annual Global Investment Conference
Marketwire - Wed Aug 28, 8:00AM CDT
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company commercializing its European Union approved CytoSorb(R) blood filter to treat life-threatening illnesses in the intensive care unit, President and Chief Executive Officer, Dr. Phillip Chan will present at the Rodman & Renshaw Annual Global Investment Conference taking place on September 8-10 in New York City.
CytoSorbents Expands CytoSorb(R) Dosing Study to Eight Clinical Trial Sites
Marketwire - Wed Aug 21, 6:00AM CDT
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company commercializing its European Union approved CytoSorb(R) blood filter to treat life-threatening illnesses in the intensive care unit, announced today the formal expansion of its CytoSorb(R) dosing study to eight leading clinical trial sites in Germany.
OTC Daily Alert Stock Watch - CytoSorbents (OTCQB: CTSO)
WorldStockWire - Thu Aug 15, 10:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
CytoSorbents to Host Shareholder Update Conference on Wednesday, August 21st at 4:15 p.m. Eastern
Marketwire - Wed Aug 14, 11:01AM CDT
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company working to save lives through blood purification, today announced that management will host a shareholder update conference call on Wednesday, August 21st at 4:15 p.m. Eastern. Management kindly asks all interested participants to submit their questions to Alliance Advisors at valter@allianceadvisors.net.
CytoSorbents Provides Corporate Update and Reports Financial Results for the Period Ended June 30, 2013
Marketwire - Wed Aug 14, 7:10AM CDT
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company commercializing its European Union approved CytoSorb(R) blood filter to treat life-threatening illnesses in the intensive care unit, provides a corporate update and reports its financial results for the three and six month period ending June 30, 2013.
CytoSorbents Selected to Present on HemoDefend(TM) at the Military Health System Research Symposium
Marketwire - Fri Jul 26, 5:00AM CDT
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company working to save lives through blood purification, announced that it has been selected to make a presentation of its HemoDefend(TM) blood purification technology at the Military Health System Research Symposium (MHSRS), the premier U.S. scientific meeting focused on medical advances that address the unique medical needs of the warfighter.
CytoSorbents Appoints Dr. Rainer Kosanke as European Director of Scientific Affairs
GlobeNewswire - Mon Jul 08, 8:00AM CDT
CytoSorbents Corporation (OTCBB:CTSO), a critical care focused company commercializing its European Union approved CytoSorb(R) blood filter to treat life-threatening illnesses in the intensive care unit, announced today that its wholly-owned subsidiary, CytoSorbents Europe GmbH has appointed Dr. Rainer Kosanke, PhD, as European Director of Scientific Affairs.
CytoSorbents Announces Start of $1M US Army Phase II SBIR Contract and Closing of Additional Funding
GlobeNewswire - Thu Jun 27, 8:00AM CDT
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company commercializing its European Union approved CytoSorb(R) blood filter to treat life-threatening illnesses in the intensive care unit, announced today that it has successfully completed negotiations and begun work on the previously announced $1 million Phase II SBIR (Small Business Innovation Research) contract in trauma and burn injury from the United States Army.
CytoSorbents Announces FDA Approved US Air Force Funded Human Trauma Pilot Study for Rhabdomyolysis
GlobeNewswire - Mon Jun 17, 7:00AM CDT
CytoSorbents Corporation (OTCBB:CTSO), a critical care focused company using blood purification to treat life-threatening illnesses in the intensive care unit, announced today that the United States Food and Drug Administration (FDA) has granted approval to begin a U.S.-based human pilot study using CytoSorb(R) for the treatment of rhabdomyolysis as a result of trauma under an Investigational Device Exemption (IDE). Rhabdomyolysis is caused by the massive release of myoglobin from severely injured skeletal muscle that can lead to kidney failure. The study was initiated by and will be funded by the U.S. Air Force. CytoSorbents is the official sponsor of the study, and expects the study to begin this year.
CytoSorbents Enters Into Exclusive Distribution Agreement for CytoSorb(R) With Hitit Medical Systems in Turkey
GlobeNewswire - Thu Jun 13, 8:06AM CDT
CytoSorbents Corporation (OTCBB:CTSO), a critical care focused therapeutic device company using blood purification to treat life-threatening illnesses, announced today that is has entered into an exclusive distribution agreement with Hitit Medical Systems to distribute CytoSorb(R) in Turkey. The initial term of the agreement is three years, and is subject to annual minimum guaranteed orders of CytoSorb(R) to maintain exclusivity.
CytoSorbents Featured in MedCity News
PR Newswire - Wed May 29, 8:00AM CDT
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to treat life-threatening illnesses in the intensive care unit, was recently featured in the article "Blood Purification Device for ICU Patients Seeks to Treat Root Cause of Sepsis" on May 24, 2013 in MedCity News.
CytoSorbents Corporation Announces $10,200,000 Registered Direct Offering
PR Newswire - Fri Mar 07, 8:31AM CST
CytoSorbents Corporation (OTCBB: CTSO), a Nevada corporation, today announced that it has entered into subscription agreements with certain institutional investors to sell approximately $10,200,000 of its common stock and warrants to purchase common stock in a registered direct offering.
Vista Partners Publishes March 2014 Macroeconomic & Investment Newsletter
Marketwire - Fri Mar 07, 8:00AM CST
Vista Partners ("Vista") announced today that it published its FREE Macroeconomic & Investment Monthly Newsletter for the month of March. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary.
National Institutes of Health Grant Urges Latino Males to Receive Free Confidential HIV Testing
PR Newswire - Wed Jan 29, 7:30AM CST
Today marks the launch of "Conoces a Pepe? Have you met Pepe?," a social impact campaign focusing on educating and mobilizing Hispanic/Latino communities to live their best life with HIV testing and taking responsibility for their health.
Stryker Hits 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 9:20AM CST
Shares of Stryker Corporation were favorably affected by its announcement of acquiring Irvine, Calif.-based Patient Safety Technologies
CytoSorbents to Exhibit at the 43rd Society of Critical Care Medicine Congress and Present at the Biotech Showcase 2014
Marketwire - Tue Jan 07, 8:01AM CST
CytoSorbents Corporation (OTCBB: CTSO), a critical care immunotherapy company, announced that it will exhibit its CytoSorb(R) and HemoDefend(TM) technologies at the Society of Critical Care Medicine (SCCM) 43rd Critical Care Congress from January 10-12, 2014 at the Moscone Center South in San Francisco, California in Booth 918. More than 4,000 critical care clinicians from the U.S. and abroad are expected to attend.
CytoSorbents Reports on Successful DIVI 2013 Conference
Marketwire - Mon Dec 16, 7:31AM CST
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company commercializing its European Union approved CytoSorb(R) blood filter to treat life-threatening illnesses in the intensive care unit, reports on its recent activities at the DIVI 2013 Congress in Leipzig, Germany.
Biocon Partners With CytoSorbents to Market CytoSorb(R) -- A 'First-in-Class' Therapy for Sepsis Management
Marketwire - Fri Sep 13, 7:01AM CDT
Biocon Ltd, Asia's largest biotech company, and CytoSorbents Corporation (OTCQB: CTSO), based in the United States, announced today, World Sepsis Day, that they have entered into a strategic partnership with an initial distribution agreement for India and select emerging markets, under which Biocon will have the exclusive commercialization rights for CytoSorb(R), a novel therapy for the management of sepsis.
Stop Sepsis. Save Lives. CytoSorbents Sponsors Global Sepsis Alliance and Sepsis Heroes in Honor of World Sepsis Day
Marketwire - Thu Sep 12, 5:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a leading innovator in the use of blood purification to treat critical illnesses such as sepsis, is a proud sponsor of both the Global Sepsis Alliance and the Sepsis Heroes event hosted by the Sepsis Alliance tonight in New York City, in honor of the second annual World Sepsis Day tomorrow.
CytoSorbents Awarded $203K Phase I SBIR Contract from NHLBI/NIH for HemoDefend(TM)
Marketwire - Mon Sep 09, 11:45AM CDT
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company specializing in blood purification, announced today that the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded the Company a Phase I SBIR (Small Business Innovation Research) contract to further advance its HemoDefend(TM) blood purification technology for packed red blood cell (pRBC) transfusions. The project, entitled "Elimination of blood contaminants from pRBCs using HemoDefend hemocompatible porous polymer beads," is valued at $203,351 over 6 months, with funding to start immediately.
CytoSorbents to Present at the Rodman & Renshaw Annual Global Investment Conference
Marketwire - Wed Aug 28, 8:00AM CDT
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company commercializing its European Union approved CytoSorb(R) blood filter to treat life-threatening illnesses in the intensive care unit, President and Chief Executive Officer, Dr. Phillip Chan will present at the Rodman & Renshaw Annual Global Investment Conference taking place on September 8-10 in New York City.
CytoSorbents Expands CytoSorb(R) Dosing Study to Eight Clinical Trial Sites
Marketwire - Wed Aug 21, 6:00AM CDT
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company commercializing its European Union approved CytoSorb(R) blood filter to treat life-threatening illnesses in the intensive care unit, announced today the formal expansion of its CytoSorb(R) dosing study to eight leading clinical trial sites in Germany.
OTC Daily Alert Stock Watch - CytoSorbents (OTCQB: CTSO)
WorldStockWire - Thu Aug 15, 10:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
CytoSorbents to Host Shareholder Update Conference on Wednesday, August 21st at 4:15 p.m. Eastern
Marketwire - Wed Aug 14, 11:01AM CDT
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company working to save lives through blood purification, today announced that management will host a shareholder update conference call on Wednesday, August 21st at 4:15 p.m. Eastern. Management kindly asks all interested participants to submit their questions to Alliance Advisors at valter@allianceadvisors.net.
CytoSorbents Provides Corporate Update and Reports Financial Results for the Period Ended June 30, 2013
Marketwire - Wed Aug 14, 7:10AM CDT
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company commercializing its European Union approved CytoSorb(R) blood filter to treat life-threatening illnesses in the intensive care unit, provides a corporate update and reports its financial results for the three and six month period ending June 30, 2013.
CytoSorbents Selected to Present on HemoDefend(TM) at the Military Health System Research Symposium
Marketwire - Fri Jul 26, 5:00AM CDT
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company working to save lives through blood purification, announced that it has been selected to make a presentation of its HemoDefend(TM) blood purification technology at the Military Health System Research Symposium (MHSRS), the premier U.S. scientific meeting focused on medical advances that address the unique medical needs of the warfighter.
CytoSorbents Appoints Dr. Rainer Kosanke as European Director of Scientific Affairs
GlobeNewswire - Mon Jul 08, 8:00AM CDT
CytoSorbents Corporation (OTCBB:CTSO), a critical care focused company commercializing its European Union approved CytoSorb(R) blood filter to treat life-threatening illnesses in the intensive care unit, announced today that its wholly-owned subsidiary, CytoSorbents Europe GmbH has appointed Dr. Rainer Kosanke, PhD, as European Director of Scientific Affairs.
CytoSorbents Announces Start of $1M US Army Phase II SBIR Contract and Closing of Additional Funding
GlobeNewswire - Thu Jun 27, 8:00AM CDT
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company commercializing its European Union approved CytoSorb(R) blood filter to treat life-threatening illnesses in the intensive care unit, announced today that it has successfully completed negotiations and begun work on the previously announced $1 million Phase II SBIR (Small Business Innovation Research) contract in trauma and burn injury from the United States Army.
CytoSorbents Announces FDA Approved US Air Force Funded Human Trauma Pilot Study for Rhabdomyolysis
GlobeNewswire - Mon Jun 17, 7:00AM CDT
CytoSorbents Corporation (OTCBB:CTSO), a critical care focused company using blood purification to treat life-threatening illnesses in the intensive care unit, announced today that the United States Food and Drug Administration (FDA) has granted approval to begin a U.S.-based human pilot study using CytoSorb(R) for the treatment of rhabdomyolysis as a result of trauma under an Investigational Device Exemption (IDE). Rhabdomyolysis is caused by the massive release of myoglobin from severely injured skeletal muscle that can lead to kidney failure. The study was initiated by and will be funded by the U.S. Air Force. CytoSorbents is the official sponsor of the study, and expects the study to begin this year.
CytoSorbents Enters Into Exclusive Distribution Agreement for CytoSorb(R) With Hitit Medical Systems in Turkey
GlobeNewswire - Thu Jun 13, 8:06AM CDT
CytoSorbents Corporation (OTCBB:CTSO), a critical care focused therapeutic device company using blood purification to treat life-threatening illnesses, announced today that is has entered into an exclusive distribution agreement with Hitit Medical Systems to distribute CytoSorb(R) in Turkey. The initial term of the agreement is three years, and is subject to annual minimum guaranteed orders of CytoSorb(R) to maintain exclusivity.
CytoSorbents Featured in MedCity News
PR Newswire - Wed May 29, 8:00AM CDT
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to treat life-threatening illnesses in the intensive care unit, was recently featured in the article "Blood Purification Device for ICU Patients Seeks to Treat Root Cause of Sepsis" on May 24, 2013 in MedCity News.
